Hospital
Northern Montana Hospital
Northern Montana Hospital was paid $950K by Medicaid between Jan 2018 and Dec 2024, across 177 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoNORTHERN MONTANA HOSPITAL
HAVRE, MT 59501
HAVRE, MT 59501
33aNPI1427059070assigned 08/04/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$950K
24GClaims350,879
24DCodes billed177
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Montana
Rank by total paid#5 of 10
Median peer was paid$774K
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,182 | $121K | |
| 2019 | 47,723 | $107K | |
| 2020 | 45,835 | $132K | |
| 2021 | 59,857 | $166K | |
| 2022 | 58,213 | $140K | |
| 2023 | 53,191 | $185K | |
| 2024incomplete | 34,878 | $99K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 15,928 | 13,783 | $199K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 14% | 12,137 | 10,831 | $136K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.8% | 2,243 | 1,939 | $64K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.2% | 2,507 | 2,117 | $59K |
| G0378 | Hospital observation service, per hour | 5.2% | 2,326 | 1,514 | $49K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.3% | 8,102 | 2,099 | $31K |
| 80050 | General health panel | 2.7% | 4,344 | 4,054 | $26K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.5% | 3,184 | 2,774 | $24K |
| 80053 | Comprehensive metabolic panel | 2.0% | 16,860 | 13,364 | $19K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.0% | 1,367 | 1,266 | $19K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 3,246 | 2,866 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 20,504 | 16,233 | $16K |
165 more codes
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 4,200 | $13K |
| J3490 | Unclassified drugs | 1.2% | 26,442 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 5,421 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.0% | 2,299 | $10K |
| 87400 | <1% | 3,403 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,355 | $9K |
| 81001 | <1% | 15,056 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,318 | $8K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,802 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 703 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,215 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,357 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,526 | $6K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 136 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 325 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 168 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,837 | $6K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,522 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,263 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 524 | $5K |
| 80061 | Lipid panel | <1% | 3,744 | $5K |
| 82728 | <1% | 1,776 | $5K | |
| 70486 | <1% | 77 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,118 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,839 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,894 | $4K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,936 | $4K |
| 84703 | <1% | 2,333 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 221 | $4K |
| 87040 | <1% | 2,283 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 246 | $3K |
| 87186 | <1% | 2,461 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,279 | $3K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 809 | $3K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 14,601 | $3K |
| 87077 | <1% | 2,424 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 230 | $3K |
| 76801 | <1% | 965 | $3K | |
| 80055 | <1% | 1,093 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 26 | $3K |
| 84439 | <1% | 3,106 | $3K | |
| 73610 | <1% | 380 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,145 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,350 | $2K |
| 82607 | <1% | 1,099 | $2K | |
| 81025 | <1% | 4,578 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 120 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,066 | $2K |
| 99285 | Emergency room visit (most serious) | <1% | 125 | $2K |
| 83690 | <1% | 2,834 | $2K | |
| 87081 | <1% | 1,778 | $2K | |
| 97161 | <1% | 578 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 99 | $2K |
| 87807 | <1% | 323 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,068 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,622 | $2K |
| 74019 | <1% | 224 | $2K | |
| 84481 | <1% | 723 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,647 | $2K |
| 83540 | <1% | 885 | $1K | |
| 83550 | <1% | 692 | $1K | |
| 87210 | <1% | 2,969 | $1K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,118 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 372 | $1K |
| 86803 | <1% | 1,772 | $1K | |
| 73630 | <1% | 280 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,147 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,205 | $991.16 |
| 83605 | <1% | 1,214 | $929.76 | |
| 73110 | <1% | 87 | $874.21 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,109 | $843.15 |
| 85651 | <1% | 2,085 | $793.91 | |
| 82150 | <1% | 1,380 | $770.56 | |
| 87070 | <1% | 1,668 | $760.36 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,068 | $737.51 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 37 | $727.59 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 467 | $692.83 |
| 73130 | <1% | 163 | $681.70 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,963 | $632.13 |
| 84484 | <1% | 3,198 | $619.51 | |
| 85027 | <1% | 519 | $547.86 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,800 | $493.52 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 152 | $473.47 |
| 85610 | <1% | 2,540 | $443.51 | |
| 87634 | <1% | 43 | $420.75 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,301 | $416.30 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 722 | $394.43 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,641 | $390.65 |
| 82947 | <1% | 1,428 | $372.20 | |
| 73562 | <1% | 105 | $344.02 | |
| 87075 | <1% | 394 | $327.16 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,985 | $306.91 |
| 87205 | <1% | 1,005 | $295.13 | |
| 86677 | <1% | 177 | $288.95 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 69 | $284.75 |
| 87653 | <1% | 416 | $274.85 | |
| 82950 | <1% | 757 | $269.35 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,203 | $205.00 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 288 | $187.94 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,020 | $179.35 |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 389 | $175.10 |
| 82746 | <1% | 15 | $172.55 | |
| 85378 | <1% | 753 | $152.83 | |
| 90715 | <1% | 29 | $138.54 | |
| 85730 | <1% | 259 | $137.70 | |
| 80076 | <1% | 149 | $106.25 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 110 | $104.98 |
| 86850 | <1% | 192 | $103.69 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 31 | $88.61 |
| 83735 | <1% | 1,179 | $87.93 | |
| 86900 | <1% | 243 | $53.54 | |
| 86901 | <1% | 258 | $52.69 | |
| 86308 | <1% | 12 | $41.22 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 729 | $24.89 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,084 | $13.70 |
| 86140 | <1% | 455 | $9.83 | |
| 86592 | <1% | 95 | $8.10 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 927 | $0.00 |
| 86703 | 0% | 1,928 | $0.00 | |
| 81003 | 0% | 34 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 155 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 96 | $0.00 |
| 84550 | 0% | 213 | $0.00 | |
| 76000 | 0% | 13 | $0.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 75 | $0.00 |
| 82570 | 0% | 79 | $0.00 | |
| 73030 | 0% | 72 | $0.00 | |
| 94060 | 0% | 14 | $0.00 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 186 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 18 | $0.00 |
| 74018 | 0% | 16 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 17 | $0.00 |
| 90791 | Psychiatric diagnostic evaluation | 0% | 29 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 28 | $0.00 |
| 84702 | 0% | 106 | $0.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 51 | $0.00 |
| 80326 | 0% | 17 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 23 | $0.00 |
| 96367 | 0% | 87 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 57 | $0.00 |
| 80364 | 0% | 17 | $0.00 | |
| 85045 | 0% | 54 | $0.00 | |
| 84145 | 0% | 14 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 1,162 | $0.00 |
| 36591 | 0% | 138 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 563 | $0.00 |
| A9270 | Non-covered item or service | 0% | 501 | $0.00 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 0% | 54 | $0.00 |
| 87340 | 0% | 67 | $0.00 | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 0% | 62 | $0.00 |
| 83880 | 0% | 207 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 13 | $0.00 |
| 88142 | 0% | 170 | $0.00 | |
| 83615 | 0% | 65 | $0.00 | |
| 76830 | Ultrasound, transvaginal | 0% | 13 | $0.00 |
| 86141 | 0% | 94 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 15 | $0.00 |
| 88304 | 0% | 12 | $0.00 | |
| 94760 | 0% | 13 | $0.00 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 0% | 14 | $0.00 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | 0% | 19 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 39 | $0.00 |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 15 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 30 | $0.00 |
| 76536 | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARADA, KEVIN (PRESIDENT/CEO)
Parent organizationNORTHERN MONTANA HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Northern Montana Hospital | Havre, MT | $2.31M |
| Northern Montana Hospital | Havre, MT | $173K |
| Northern Montana Vision Center | Havre, MT | $67K |
| Northern Montana Hospital | Havre, MT | $37K |
| Northern Montana Hospital | Havre, MT | $144.57 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.